Inflammatory Markers and Prognosis After Cerebral Thrombectomy in Large Vessel Occlusion
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorZhongshan Hospital Xiamen University
About this trial
The goal of this observational study is to describe the local change in interleukin-6 (IL-6) across a blood clot in adults with acute ischemic stroke caused by anterior circulation large vessel occlusion who are undergoing mechanical thrombectomy.
The main questions it aims to answer are:
* Is the level of IL-6 different in arterial blood collected beyond the clot compared with arterial blood collected before the clot during mechanical thrombectomy? * Is the trans-thrombus IL-6 difference associated with functional independence 90 days after stroke and with complications related to reperfusion injury? There is no comparison group and no experimental treatment. Researchers will compare paired blood samples collected from opposite sides of the clot in the same participant. Blood collected from a peripheral vein at hospital admission will be used only as a supportive reference for systemic inflammation.
Participants will:
* Receive standard mechanical thrombectomy and stroke care determined by their treating clinical team. * Have small blood samples collected at planned time points, including paired arterial blood samples collected during the thrombectomy procedure. * Have clinical and imaging information collected from their medical records and have functional status assessed 90 days after stroke.
The study will not delay or change standard stroke treatment.
Eligibility criteria
Qualifiers
Age 18 years or older.
Acute ischemic stroke caused by anterior circulation large vessel occlusion, confirmed by routine vascular imaging or digital subtraction angiography.
Undergoing clinically indicated mechanical thrombectomy according to routine clinical practice.
Provision of written informed consent by the participant or legally authorized representative, in accordance with local ethics requirements.
Disqualifiers
Posterior circulation large vessel occlusion.
Mechanical thrombectomy not performed.
Known active systemic infection, active malignancy, or chronic inflammatory/autoimmune disease requiring systemic immunosuppressive treatment, when these conditions are expected to substantially affect inflammatory biomarker measurements.
Pregnancy or breastfeeding, if required by the local ethics committee.
Trial design
Treatments tested in this trial
- Prospective Mechanical Thrombectomy Cohort
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov